Overview of Dr. Lancet
Dr. Jeffrey Lancet is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from SUNY Upstate Medical University and has been in practice 25 years. Dr. Lancet accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.
Office
12902 Usf Magnolia Dr
Tampa, FL 33612Fax+1 813-745-3071
Education & Training
- University of RochesterFellowship, Hematology and Medical Oncology, 1996 - 1999
- Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1995 - 1996
- University of RochesterResidency, Internal Medicine, 1992 - 1995
- SUNY Upstate Medical UniversityClass of 1992
Certifications & Licensure
- FL State Medical License Current
- FL State Medical License 2004 - 2025
- NY State Medical License 1994 - 2006
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation Start of enrollment: 2006 May 01
- Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Start of enrollment: 2006 Aug 01
- Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy Start of enrollment: 2006 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsMolecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia.Terrence Bradley, Deukwoo Kwon, Jorge Monge, Mikkael Sekeres, Namrata Chandhok
Ejhaem. 2022-11-01 - 44 citationsMagrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic
Journal of Clinical Oncology. 2023-05-20 - 56 citationsCutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.Rahel Mathew, John M. Bennett, Jane Jijun Liu, Rami S. Komrokji, Jeffrey E. Lancet
Leukemia Research. 2012-01-01
Journal Articles
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
- A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AMLEytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Abstracts/Posters
- Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 MutationJeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical StateJeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic SyndromeJeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- AML: Expert Guidance on Current Standards and New Directions in Patient Care61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
- State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017
Press Mentions
- COVID-19 Takes a Toll on People with Blood Cancers and DisordersDecember 11th, 2021
- New AML Approvals Changing the Treatment LandscapeSeptember 8th, 2017
- Emerging Agents Poised to Transform AML LandscapeJuly 17th, 2017
- Join now to see all
Grant Support
- UM-1 North American Star ConsortiumNIH/NCI2020–2026
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
Anthem KeyCare PPO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open AccessCIGNA PPO
Coventry Carelink Health Plans PPO
Coventry Florida - Employer Group PPO
Coventry Virginia - HMO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Network Health Plan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust POS-SE
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: